Trial Profile

A Phase I, Single Center, Open-Label, Randomized, 3-Period, 3-Sequence Crossover Study to Assess the Pharmacokinetics (PK) of XEN901 Pediatric Formulation (Granules), the Impact of Food (High-Fat Meal) on this Formulation, and its Relative Bioavailability to an Adult Immediate Release (IR) Tablet Formulation

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 21 Jan 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Dec 2020 Results presented at the 74th Annual Meeting of the American Epilepsy Society
07 Dec 2020 According to a Xenon Pharmaceuticals media release, data from this study was presented at the AES2020, the virtual Annual Meeting of the American Epilepsy Society.
07 Dec 2020 Results published in the Xenon Pharmaceuticals Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com